A rapid, easy, and scalable whole blood monocyte CD169 assay for outpatient screening during SARS-CoV-2 outbreak, and potentially other emerging disease outbreaks.
Moïse MichelFabrice MalergueInès Ait BelkacemPénélope BourgoinPierre-Emmanuel MorangeIsabelle ArnouxTewfik MiloudMatthieu MillionHervé Tissot-DupontJean-Louis MegeJoana VitteJean-Marc BusnelPublished in: SAGE open medicine (2022)
Monocyte CD169 evaluation was highly sensitive for detecting SARS-CoV-2 infection in first-presentation patients; and it returns to basal level upon infection clearance. The potential ease of fingerprick collection, minimal time-to-result, and low cost rank this biomarker measurement as a potential viral disease screening tool, including COVID-19. When the virus prevalence in the tested population is usually low (1%-10%), such an approach could increase the testing capacity 10 to 100-fold, with the same limited molecular testing resources, which could focus on confirmation purposes only.
Keyphrases
- sars cov
- low cost
- respiratory syndrome coronavirus
- end stage renal disease
- dendritic cells
- coronavirus disease
- ejection fraction
- chronic kidney disease
- newly diagnosed
- endothelial cells
- risk factors
- peritoneal dialysis
- prognostic factors
- peripheral blood
- high throughput
- human health
- mass spectrometry
- case report
- patient reported outcomes
- patient reported
- sensitive detection